Condition
Dermatitis Herpetiformis
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Terminated1
Unknown1
Enrolling By Invitation1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05597904Recruiting
Background of Different Phenotypes of Coeliac Disease
NCT05998291Enrolling By InvitationPrimary
Dermatitis Herpetiformis Refractory to Gluten Free Diet
NCT00962182Phase 1Completed
Study of Enzyme Supplements to Treat Celiac Disease
NCT01115244Phase 4TerminatedPrimary
Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
NCT01952275Unknown
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Showing all 5 trials